{"entity":{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","aka":[],"tldr":"Making CAR-T cells at or near the hospital instead of shipping cells to a central factory and back.","summary":"Academic centres (Sheba, Hospital Clínic Barcelona's ARI-0001, several Chinese and Indian programmes) and companies (Cellares 'Smart Factories', Orgenesis, Galapagos' decentralised model) manufacture cell therapies close to the patient, cutting vein-to-vein time to about a week and cost substantially. Regulators are working out how to license many small sites against one product specification.","status":"emerging","asOf":"2026-09-08","links":[{"label":"FDA guidance: considerations for the development of CAR T cell products","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["closed-automated-cell-manufacturing","car-t"],"targets":[],"drugs":[],"companies":["cellares","galapagos"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":["closed-automated-cell-manufacturing"],"notes":[],"principle":"Standardised closed platforms plus centralised quality oversight and digital batch records allow the same process to run at many sites.","strengths":["Days rather than weeks to product","Lower cost","Access for hospitals far from central plants"],"limitations":["Regulatory model immature outside a few jurisdictions","Site-to-site comparability","Vector supply still centralised"]},"route":"/technologies/point-of-care-cell-manufacturing/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/"}],"company":[{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/"},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/"},{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","route":"/companies/immuneel/"},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/"},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/"}],"person":[{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/"}],"paper":[{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/"}],"term":[{"id":"vein-to-vein-time","kind":"term","name":"Vein-to-vein time and manufacturing slots","route":"/terms/vein-to-vein-time/"}],"institution":[{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/"},{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/"},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/"}],"drug":[{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/"},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/"}],"trial":[{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/"},{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/"}]}}